OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:38 UTC. Every row links to its source record.

LIN28B lin-28 RNA binding posttranscriptional regulator B

ENSG00000187772 · protein coding · Open Targets profile

Suppressor of microRNA (miRNA) biogenesis, including that of let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and sequester them in the nucleolus, away from the microprocessor complex, hence preventing their processing into mature miRNA (PubMed:22118463). Does not act on pri-miR21 (PubMed:22118463). The repression of let-7 expression is required for normal development and contributes to maintain the pluripotent state of embryonic stem cells by preventing let-7-mediated differentiation. When overexpressed, recruits ZCCHC11/TUT4 uridylyltransferase to pre-let-7 transcripts, leading to their terminal uridylation and degradation (PubMed:19703396). This activity might not be relevant in vivo, as LIN28B-mediated inhibition of let-7 miRNA maturation appears to be ZCCHC11-independent (PubMed:22118463). Interaction with target pre-miRNAs occurs via an 5'- GGAG-3' motif in the pre-miRNA terminal loop. Mediates MYC-induced let- 7 repression (By similarity). When overexpressed, isoform 1 stimulates growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no effect on cell growth. {ECO:0000250|UniProtKB:Q45KJ6, ECO:0000269|PubMed:16971064, ECO:0000269|PubMed:18951094, ECO:0000269|PubMed:19703396, ECO:0000269|PubMed:22118463}.

In 3 of 15 cancers, the evidence for LIN28B comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751benign prostatic hyperplasiabenign prostatic hyperplasiabenign prostatic hyperplasia: germline 0.42neuroblastomaneuroblastomaneuroblastoma: germline 0.05pancreatic ductal adenocarcinomapancreatic ductal adenocarcinomacolonic neoplasmcolonic neoplasmhepatocellular carcinomahepatocellular carcinomamalignant colon neoplasmmalignant colon neoplasmcolorectal carcinomacolorectal carcinomalobular capilliary hemangiomalobular capilliary hemangiomalobular capilliary hemangioma: germline 0.17ovarian carcinomaovarian carcinomaovarian cancerovarian canceroral cavity squamous cell carcinomaoral cavity squamous cell carcinomalung carcinomalung carcinomalung cancerlung canceracute myeloid leukemiaacute myeloid leukemialeukemialeukemia

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

No positive tractability buckets.

gnomAD loss of function constraint: o/e 0.228410005569458 (upper bound 0.4802600145339966). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of LIN28B's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of LIN28B's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.